The Food and Drug Administration (FDA) recently approved tirzepatide, marketed as Zepbound, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This marks the first FDA-approved drug specifically for treating OSA. The announcement came in a December 20th press release, signifying a significant advancement in sleep apnea treatment options. The FDA recommends using Zepbound in conjunction with lifestyle changes, such as calorie reduction and increased physical activity.
Obstructive sleep apnea, a serious sleep disorder, occurs when the upper airway becomes blocked during sleep, leading to pauses in breathing. These interruptions can significantly impact sleep quality and overall health. According to Dr. Sally Seymour, director of the Division of Pulmonology, Allergy, and Critical Care in the FDA’s Center for Drug Evaluation and Research, this approval represents a “major step forward” for individuals struggling with OSA.
:max_bytes(150000):strip_icc():focal(749×0:751×2)/philips-sleep-apnea-machine-1-020224-0db04637f7594fd88110813b90a11114.jpg)
The FDA’s decision is based on two comprehensive 52-week studies involving obese adults with moderate to severe sleep apnea. These studies demonstrated that Zepbound, a GLP-1 receptor agonist, significantly reduced episodes of shallow breathing or temporary pauses in breathing compared to a placebo. This positive impact was observed in both participants who used a continuous positive airway pressure (CPAP) machine and those who did not. The drug’s effectiveness is attributed to its weight loss benefits, which play a crucial role in alleviating sleep apnea symptoms.
The American Academy of Sleep Medicine (AASM) supports the FDA’s authorization of Zepbound for sleep apnea treatment. However, they emphasize that this medication is not a universal solution for all sleep apnea cases. While obesity is a primary risk factor for sleep apnea, other factors, such as jaw and upper airway structure, can also contribute to the condition. The AASM underscores that continued weight loss is essential for Zepbound to remain effective in managing sleep apnea symptoms.
:max_bytes(150000):strip_icc():focal(749×0:751×2)/philips-sleep-apnea-machine-tout-1-020224-465750f6832944f28d11c454afd41ac1.jpg)
The approval of Zepbound for sleep apnea follows a trend of weight loss drugs being recognized for their potential in treating conditions beyond obesity and diabetes. Earlier this year, Wegovy, another GLP-1 receptor agonist, received FDA approval for preventing strokes and heart attacks in certain individuals. Research is ongoing to explore the potential benefits of GLP-1 medications in addressing other health issues, including addiction and certain types of cancer.
